- Phone: +1 (808) 261-4476
- Mon-Fri (8am - 4:30pm)
- info@hawaiineuroscience.com
Sociodemographic Disparities and Risk Factors in Diagnosing Idiopathic Intracranial Hypertension: A Retrospective Case-Control Study.
Frances Morden Charissa Tan, Enrique Carrazana, Jason Viereck, Kore Kai Liow, Arash Ghaffari-Rafi. J of Neurosurgery Supplements 2021
Assessing U.S. Demographic Recruitment Bias in 21st Century Neurosurgery Clinical Trials.
Taylor E, Buffenstein I, Kāneakua B, Ghaffari-Rafi A, Viereck J, Carrazana E, Liow K. J of Neurosurgery Supplements 2021
Effectiveness of Dual Migraine therapy with CGRP Antagonists and OnabotulinumtoxinA Injections: Experience from a Single Migraine Center in Hawaii.
Lee J, Liang Y, Newman B, Tamanaha R, Toni T, Carrazana E, Vajjala V, Viereck J, Liow K. Cephalgia 40 (IS), 2020 Pg. 104
COVID-19 Pandemic Effect on Epilepsy Outpatient Care at a Regional Referral Center in Hawaii.
Nakamoto M, Smith M, Crocker J, Morden F, Liu K, Ma E, Chong A, Van N, Mitchell C, Zhu E, Dang N, Carrazana E, Viereck J, Liow K. Epilepsia Supplements December, 2020
Biopsychological predictors in patients with psychogenic non-epileptic seizures from a comprehensive epilepsy center in Hawai’i
C Lu, R Ho, J Ocol, M Yang, E Carrazana, K Liow, Epilepsia Supplements December, 2019
Use of Cannabinoids in Patients with Epilepsy from a Comprehensive Epilepsy Center in Hawaii.
R Ho, J Zhang, C Lu, B Fong, K Oura, A Shipman, H Hu, A Appana, G Slattery, E Carrazana , K Liow, Epilepsia Supplements December, 2019
Presentation of PNES in Hawaii’s Ethnoculturally Diverse Patients
Ocol J, Ho R, Lu C, Dolim S, Yang M, Kaplan A, Wilson C, Lee E, Carrazana E. Liow K. 2018 American Epilepsy Society Meeting, Epilepsia 2018.
Factors that Affect the Employability of Patients with Epilepsy in Hawaii: A Look at Race, Comorbidities, and Marital Status.
Gorenflo R, Kimball L, Taeza B, Gan A, Carrazana E, Liow K.
American Academy of Neurology Annual Meeting, April 2021
Effectiveness of Dual Migraine therapy with CGRP Antagonists and OnabotulinumtoxinA Injections: Experience from a Single Migraine Center in Hawaii.
Lee J, Liang Y, Newman B, Tamanaha R, Toni T, Carrazana E, Vajjala V, Viereck J, Liow K.
2020 International Headache Society Annual Meeting
COVID-19 Pandemic Effect on Epilepsy Outpatient Care at a Regional Referral Center in Hawaii.
Nakamoto M, Smith M, Crocker J, Morden F, Liu K, Ma E, Chong A, Van N, Mitchell C, Zhu E, Dang N, Carrazana E, Viereck J, Liow K.
74th Annual Meeting of the American Epilepsy Society Meeting, Seattle, WA, Dec 2020
Use of Cannabinoids in Patients with Epilepsy from a Comprehensive Epilepsy Center in Hawaii.
American Epilepsy Society Annual Meeting, Baltimore, MD, Dec, 2019
Biopsychological predictors in patients with psychogenic non-epileptic seizures from a comprehensive epilepsy center in Hawai’i,
American Epilepsy Society Annual Meeting, Baltimore, MD, Dec, 2019
Nair DR, Laxer KD, Weber PB et al. Nine-Year Prospective Efficacy And Safety Of Brain-Responsive Neurostimulation For Focal Epilepsy. Neurology.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. PubMed PMID: 32757523
Vagal Nerve Stimulation (VNS) in genetic developmental epileptic encephalopathies (DEE): approach in highly specialized centers around the world. Kwan P, Verner R, O’Brien T, El Tahry R, Keough K, Boggs J, Fahoum F, Greco T, Van Grunderbeek W, Sen A,Core-VNS Study Group. Epilepsia Supplements December, 2020
Use of a Second Dose of Diazepam Nasal Spray Within 4 Hours and Effect on the Safety Profile in Patients with Seizure Clusters: Interim Results from a Phase 3, Open-Label, 12-Month Repeat Dose Safety Study. Daniel Tarquinio, Eric B. Segal, Ian Miller, James W. Wheless, R. Edward Hogan, Victor Biton, Gregory D. Cascino, Michael R. Sperling, Kore Liow, Blanca Vazquez, Ricardo Ayala, Weldon Mauney, Jay Desai, Adrian L. Rabinowicz, Enrique Carrazana, for the DIAZ.001.05 Study Group. Epilepsia Supplements December, 2020
Efficacy and Safety Of Adjunctive Padsevonil In Adults With Drug-Resistant Focal Seizures: A Double-Blind, Randomized, Placebo-Controlled Dose-Finding Trial. Rademacher M, Toledo M, Van Paesschen W, Liow K, Esch M, Webster E, Wang N, Werhahn K, French J. Epilepsia Supplements December, 2020
Evaluation of Diazepam Nasal Spray in Patients with Epilepsy Concomitantly Using Maintenance Benzodiazepines: Interim Analysis from a Phase 3, Long-term, Open-label Safety Study. Eric B. Segal, ; Daniel Tarquinio, Ian Miller, James W. Wheless, Dennis Dlugos, Ricardo Ayala,Victor Biton, Gregory D. Cascino, Jay Desai, R. Edward Hogan, Kore Liow, Weldon Mauney, Michael R. Sperling, Blanca Vazquez, David F. Cook, Adrian L. Rabinowicz, Enrique Carrazana for the DIAZ.001.05 Study Group. Epilepsia Supplements December, 2020
CORE-VNS: A Prospective Outcomes Registry of Patients With Drug-resistant Epilepsy Treated With Vagus Nerve Stimulation Therapy. Kwan P, Verner R, O’Brien T, El Tahry R, Keough K, Boggs J, Fahoum F, Greco T, Van Grunderbeek W, Sen A,Core-VNS Study Group. 2020. Epilepsia Supplements December, 2020
Wessels AM, Barbone JM, DiGregorio DT, Miller DS, Mullen JA, Sims JR. Lanabecestat: Rater performance and error characteristics of efficacy assessments in the DAYBREAK-ALZ study. CTAD P
Two-Part, Double-Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Patients with Epilepsy with a Predictable Seizure Pattern: Results from the Initial Open-Label Feasibility Part. J French, K Liow, B Vazquez, P Klein, D Tarquinio, B Reich, R Small, J Isojarvi. Neurology Supplements 2019
Frank Nagy, Michael A. Rogawski, Hui Gong, Kore Liow, Sami Aboumater, Pavel Klein, Michael A. Gelfand, Cassie Jung, Stephen Wargacki, Rikin Mehta, Allen H. heller Pharmacokinetics of Diazepam Buccal Film in Adult Patients with Epileps
Safety Profile of Valtoco® (diazepam nasal spray) in Patients with Epilepsy: Final Results From a Phase 3, Open-Label, 12-Month Repeat Dose Safety Study. Wheless JW, Sperling MR, Liow K, Vazquez B, Segal EB, Miller I, Hogan RE, Tarquinio D, Mauney W, DeSai J, Dlugos D, Biton V, Cascino G, Carrazana E; Rabinowicz AL, for the DIAZ.001.05 Study Group. American Managed Care Pharmacist (AMCP) Annual Meeting, Virtual. April 2021
Time to Second Doses in Emergency Seizure Patients Treated with Valtoco® (diazepam nasal spray) Across 24 Hours: Subgroup Results From a Completed Phase 3, Open-label, Repeat Dose Safety Study. Wheless JW, Sperling MR, Liow K, Vazquez B, Segal EB, Miller I, Hogan RE, Tarquinio D, Mauney W, DeSai J, Dlugos D, Biton V, Cascino G, Carrazana E; Rabinowicz AL, for the DIAZ.001.05 Study Group. American Managed Care Pharmacist (AMCP) Annual Meeting, Virtual. April 2021
Evaluation of Diazepam Nasal Spray in Patients with Epilepsy Concomitantly Using Maintenance Benzodiazepines: Interim Analysis from a Phase 3, Long-term, Open-label Safety Study. Segal E, Tarquinio D, Miller I, Wheless J, Dlugos D, Biton V, Cascino G, Desai J, Hogan E, Liow K, Mauney W, Sperling M, Cook D, Rabinowicz A, Carrazana E, for the DIAZ.001.05 Study Group. American Academy of Neurology (AAN), Annual Meeting, Virtual. April 2021
Safety Profile of Valtoco® (diazepam nasal spray) in Patients With Epilepsy: Final Results From a Phase 3, Open-Label, 12-Month Repeat Dose Safety Study. Wheless JW, Sperling MR, Liow K, Vazquez B, Segal EB, Miller I, Hogan RE, Tarquinio D, Mauney W, DeSai J, Dlugos D, Biton V, Cascino G, Carrazana E; Rabinowicz AL, for the DIAZ.001.05 Study Group. American Academy of Neurology (AAN), Annual Meeting, Virtual. April 2021
Time to Second Doses in Emergency Seizure Patients Treated with Valtoco® (diazepam nasal spray) Across 24 Hours: Subgroup Results From a Completed Phase 3, Open-label, Repeat Dose Safety Study. Wheless JW, Sperling MR, Liow K, Vazquez B, Segal EB, Miller I, Hogan RE, Tarquinio D, Mauney W, DeSai J, Dlugos D, Biton V, Cascino G, Carrazana E; Rabinowicz AL, for the DIAZ.001.05 Study Group. American Academy of Neurology (AAN), Annual Meeting, Virtual. April 2021
Use of a Second Dose of Diazepam Nasal Spray Within 4 Hours and Effect on the Safety Profile in Patients with Seizure Clusters: Interim Results from a Phase 3, Open-Label, 12-Month Repeat Dose Safety Study. Daniel Tarquinio, Eric B. Segal, Ian Miller, James W. Wheless, R. Edward Hogan, Victor Biton, Gregory D. Cascino, Michael R. Sperling, Kore Liow, Blanca Vazquez, Ricardo Ayala, Weldon Mauney, Jay Desai, Adrian L. Rabinowicz, Enrique Carrazana, for the DIAZ.001.05 Study Group. 74th Annual Meeting of the American Epilepsy Society Meeting, Seattle, WA, Dec 2020.
Evaluation of Diazepam Nasal Spray in Patients with Epilepsy Concomitantly Using Maintenance Benzodiazepines: Interim Analysis from a Phase 3, Long-term, Open-label Safety Study. Eric B. Segal, ; Daniel Tarquinio, Ian Miller, James W. Wheless, Dennis Dlugos, Ricardo Ayala,Victor Biton, Gregory D. Cascino, Jay Desai, R. Edward Hogan, Kore Liow, Weldon Mauney, Michael R. Sperling, Blanca Vazquez, David F. Cook, Adrian L. Rabinowicz, Enrique Carrazana for the DIAZ.001.05 Study Group. 74th Annual Meeting of the American Epilepsy Society Meeting, Seattle, WA, Dec 2020.
Efficacy and Safety Of Adjunctive Padsevonil In Adults With Drug-Resistant Focal Seizures: A Double-Blind, Randomized, Placebo-Controlled Dose-Finding Trial. Rademacher M, Toledo M, Van Paesschen W, Liow K, Esch M, Webster E, Wang N, Werhahn K, French J. 74th Annual Meeting of the American Epilepsy Society Meeting, Seattle, WA, Dec 2020.
Vagal Nerve Stimulation (VNS) in genetic developmental epileptic encephalopathies (DEE):approach in highly specialized centers around the world. Kwan P, Verner R, O’Brien T, El Tahry R, Keough K, Boggs J, Fahoum F, Greco T, Van Grunderbeek W, Sen A,Core-VNS Study Group. 2020 74th Annual Meeting of the American Epilepsy Society Meeting, Seattle, WA, Dec 2020.
CORE-VNS: A Prospective Outcomes Registry of Patients With Drug-resistant Epilepsy Treated With Vagus Nerve Stimulation Therapy. Kwan P, Verner R, O’Brien T, El Tahry R, Keough K, Boggs J, Fahoum F, Greco T, Van Grunderbeek W, Sen A,Core-VNS Study Group. 2020 74th Annual Meeting of the American Epilepsy Society Meeting, Seattle, WA, Dec 2020.
A Randomized Phase 3 Study in
Use of Cannabinoids in Patients with Epilepsy from a Comprehensive Epilepsy Center in Hawaii. R Ho, J Zhang, C Lu, B Fong, K Oura, A Shipman, H Hu, A Appana, G Slattery, E Carrazana , K Liow, American Epilepsy Society Annual Meeting, Baltimore, MD, Dec, 2019
Biopsychological predictors in patients with psychogenic non-epileptic seizures from a comprehensive epilepsy center in Hawai’i, ,C Lu, R Ho, J Ocol, M Yang, E Carrazana, K Liow American Epilepsy Society Annual Meeting, Baltimore, MD, Dec, 2019
Willis B, James D, Scott S, Bragg S, Mullen J, Downing A, Selzler K, Wessels A, Zimmer J, Sims J. Lanabecestat: Biomarker results from two Phase 3 studies in Alzheimer’s disease. 14th International Conference on Alzheimer’s and Parkinson’s Disease (ADPD) 2019.
Mintun M, Shcherbinin S, Charil A, Zimmer J, Andersen S, Landry J, Mullen J, Wessels A, Bragg S, Selzler K, Fleisher A, Sims J. Lanabecestat: Neuroimaging re
***We Promise, no spam!
